CR20140581A - Suministro de fármaco biodegradable para las composiciones hidrofóbicas - Google Patents

Suministro de fármaco biodegradable para las composiciones hidrofóbicas

Info

Publication number
CR20140581A
CR20140581A CR20140581A CR20140581A CR20140581A CR 20140581 A CR20140581 A CR 20140581A CR 20140581 A CR20140581 A CR 20140581A CR 20140581 A CR20140581 A CR 20140581A CR 20140581 A CR20140581 A CR 20140581A
Authority
CR
Costa Rica
Prior art keywords
biodegradable drug
supply
hydrophobic compositions
polyester
polyethylene glycol
Prior art date
Application number
CR20140581A
Other languages
English (en)
Inventor
Georges Gaudriault
Christophe Roberge
Original Assignee
Medincell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140581(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medincell filed Critical Medincell
Publication of CR20140581A publication Critical patent/CR20140581A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen las composiciones de suministro de fármaco biodegradable que comprenden un copolímero tribloque que contiene un poliéster y un polietilenglicol y un copolímero dibloque que contiene un poliéster y un polietilenglicol con extremos protegidos, así como por lo menos un principio farmacéuticamente activo o un principio hidrofóbico activo como acetato de medroxiprogesterona, levonorgestrel, ciclosporina, progesterona o bupivacaína.
CR20140581A 2012-06-27 2014-12-16 Suministro de fármaco biodegradable para las composiciones hidrofóbicas CR20140581A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261665192P 2012-06-27 2012-06-27
PCT/IB2013/001547 WO2014001904A1 (en) 2012-06-27 2013-06-27 Biodegradable drug delivery for hydrophobic compositions

Publications (1)

Publication Number Publication Date
CR20140581A true CR20140581A (es) 2015-02-06

Family

ID=49117888

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140581A CR20140581A (es) 2012-06-27 2014-12-16 Suministro de fármaco biodegradable para las composiciones hidrofóbicas

Country Status (23)

Country Link
US (5) US20150150987A1 (es)
EP (1) EP2866837B1 (es)
JP (1) JP6134788B2 (es)
KR (1) KR102189442B1 (es)
CN (1) CN104582733B (es)
AU (1) AU2013282891B2 (es)
BR (1) BR112014031773B1 (es)
CA (1) CA2877083C (es)
CL (1) CL2014003531A1 (es)
CO (1) CO7160098A2 (es)
CR (1) CR20140581A (es)
CU (1) CU24287B1 (es)
EA (1) EA031522B1 (es)
ES (1) ES2938586T3 (es)
IL (1) IL236472B (es)
IN (1) IN2014DN11063A (es)
MA (1) MA37809B1 (es)
MX (1) MX353280B (es)
SG (1) SG11201408658PA (es)
TN (1) TN2014000520A1 (es)
UA (1) UA113549C2 (es)
WO (2) WO2014001904A1 (es)
ZA (1) ZA201409291B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
JP6640725B2 (ja) 2014-01-27 2020-02-05 セントレ ナショナル デ ラ レチャーチェ シャーティフィック ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20170290846A1 (en) * 2014-09-30 2017-10-12 University Of Tennessee Research Foundation In situ gelling form for long-acting drug delivery
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
FR3027522B1 (fr) 2014-10-27 2016-12-09 I Ceram Composition poreuse chargee en principe actif
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP4374861A3 (en) 2015-11-16 2024-08-07 MedinCell S.A. A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11766400B2 (en) * 2016-10-24 2023-09-26 Yale University Biodegradable contraceptive implants
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
ES3015765T3 (en) * 2017-07-17 2025-05-07 Medincell S A Pharmaceutical composition
GB2568526A (en) 2017-11-20 2019-05-22 Rebio Tech Oy Composition
CN108078911A (zh) * 2017-12-08 2018-05-29 复旦大学 用于动物避孕的热致水凝胶缓释兽药注射剂及其制备方法
ES2990218T3 (es) * 2018-08-22 2024-11-29 Bacainn Biotherapeutics Ltd Composiciones de ciclosporina y métodos de uso
GB201900258D0 (en) * 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
ES3058225T3 (en) 2019-09-13 2026-03-09 Medincell S A Drug delivery formulations
CN111700876A (zh) * 2020-03-12 2020-09-25 上海市肿瘤研究所 一种治疗系统性红斑狼疮的载药递送给药系统及其制备方法
EP4262749A1 (en) 2020-12-16 2023-10-25 Medincell S.A. Methods and compositions for the prophylactic treatment of sars-cov-2 virus (covid-19)
FI20215186A1 (en) 2021-02-19 2022-08-20 Rebio Tech Oy Compositions for ophthalmic treatment
BR112023018652A2 (pt) 2021-03-17 2023-10-03 Medincell S A Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveis
KR20240006032A (ko) * 2021-04-30 2024-01-12 메딘셀 에스.에이. 새로운 제형
WO2025081046A1 (en) * 2023-10-11 2025-04-17 The Brigham And Women's Hospital, Inc. Ultra-high drug loading injectable drug suspension of hydrophobic drugs for long-term drug delivery
WO2026013080A1 (en) 2024-07-08 2026-01-15 InnoCore Technologies Holding B.V. Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
WO2002085337A1 (en) 2001-04-20 2002-10-31 The University Of British Columbia Micellar drug delivery systems for hydrophobic drugs
CN100408099C (zh) * 2000-11-09 2008-08-06 阿斯特拉曾尼卡有限公司 含有嵌段共聚物的口服药物组合物
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US6592899B2 (en) * 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
PT1638535E (pt) * 2003-06-26 2007-11-08 Mediolanum Pharmaceuticals Ltd Implantes subcutâneos com libertação inicial de princípio activo limitada e subsequente sua libertação extensiva com variação linear
US20050112170A1 (en) * 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
AU2006278328A1 (en) * 2005-08-04 2007-02-15 Angiotech International Ag Block copolymer compositions and uses thereof
CN101273963A (zh) * 2007-11-22 2008-10-01 山东蓝金生物工程有限公司 一种含激素类抗癌药的温控缓释注射剂
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
WO2010059001A2 (ko) * 2008-11-21 2010-05-27 주식회사 삼양사 내성암 치료용 고분자 미셀 조성물 및 그 제조방법
CN101810560B (zh) * 2009-02-20 2013-07-10 北京大学 环孢a聚合物胶束组合物
MX347090B (es) * 2010-12-29 2017-04-11 Medincell Composiciones de suministro de farmacos biodegradables.

Also Published As

Publication number Publication date
US20220354956A1 (en) 2022-11-10
IL236472B (en) 2020-02-27
EP2866837B1 (en) 2022-12-14
JP6134788B2 (ja) 2017-05-24
SG11201408658PA (en) 2015-02-27
MX2014015902A (es) 2015-07-17
MX353280B (es) 2018-01-05
CA2877083A1 (en) 2014-01-02
CA2877083C (en) 2020-10-06
BR112014031773B1 (pt) 2020-10-13
CL2014003531A1 (es) 2015-08-28
ZA201409291B (en) 2017-05-31
US20190160171A1 (en) 2019-05-30
AU2013282891A2 (en) 2015-02-05
CU20140148A7 (es) 2015-03-30
EA031522B1 (ru) 2019-01-31
EP2866837A1 (en) 2015-05-06
AU2013282891A1 (en) 2015-01-22
CU24287B1 (es) 2017-12-08
MA37809A1 (fr) 2017-07-31
AU2013282891B2 (en) 2018-04-12
HK1208374A1 (en) 2016-03-04
IN2014DN11063A (es) 2015-09-25
US20200085958A1 (en) 2020-03-19
US20210008216A1 (en) 2021-01-14
CN104582733B (zh) 2017-07-04
MA37809B1 (fr) 2018-12-31
EA201492172A1 (ru) 2015-09-30
KR20150027265A (ko) 2015-03-11
IL236472A0 (en) 2015-02-26
TN2014000520A1 (en) 2016-03-30
JP2015522001A (ja) 2015-08-03
CO7160098A2 (es) 2015-01-15
UA113549C2 (xx) 2017-02-10
WO2014001904A1 (en) 2014-01-03
US20150150987A1 (en) 2015-06-04
WO2014001905A1 (en) 2014-01-03
KR102189442B1 (ko) 2020-12-11
ES2938586T3 (es) 2023-04-12
BR112014031773A2 (pt) 2017-06-27
CN104582733A (zh) 2015-04-29

Similar Documents

Publication Publication Date Title
CO7160098A2 (es) Suministro de fármaco biodegradable para las composiciones hidrofóbicas
BR112013016662A2 (pt) composições biodegradáveis para administração de fármaco
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
ECSP15013227A (es) Formulaciones acuosas estables de adalimumab
BR112015022674A2 (pt) inibidores de bromodomínio
MX384911B (es) Hibridosomas, composiciones que comprenden los mismos, procesos para su producción y usos de los mismos.
BR112013012587A2 (pt) composição farmacêutica para administração nasal
BR112015018087A8 (pt) composto, composição farmacêutica e uso
EA201390662A1 (ru) Фармацевтическая композиция, содержащая дутастерид
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
EP2643009A4 (en) COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES
EA201591830A1 (ru) Фармацевтические композиции, включающие эверолимус
MX363699B (es) Producto de comicronizacion que comprende acetato de ulipristal.
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
EP4374861A3 (en) A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
WO2013112806A3 (en) Transdermal hormone delivery
TR201803451T4 (tr) Olmesartan formülasyonlari.
NZ702849A (en) Genotype- or phenotype-based drug formulation
UA102010C2 (ru) Комбинация активных ингредиентов, которая содержит нестероидное противовоспалительное лекарственное средство и производное колхикозида
UA118654C2 (uk) Ін'єктовані склади антибіотиків і способи їх застосування
UA71540U (ru) Способ профилактики воспалительной реакции при хирургическом лечении осложненной увеальной катаракты
TR201203084A2 (tr) Sefditoren pivoksil ve klavulanik asit içeren formülasyonlar.
TR201203083A2 (tr) Sefdinir ve klavulanik asit içeren farmasötik dozaj formu.
TR201203086A2 (tr) Sefiksim ve klavulanik asit içeren farmasötik dozaj formu.
TR201203087A2 (tr) Seftibüten ve klavulanik asit formülasyonları.